Heteroaromatic compounds and their use as dopamine D1 ligands
US10077272B2 · kind B2 · utility
0Cited by
20References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 27, 2017 |
| Grant date | Sep 18, 2018 |
| Priority date | — |
| Expiry date | Nov 27, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.